NSCLC Hub Header
opdivo-dtc-util-nav

Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user spending time outdoors with his grandchildren.
Potential OPDIVO® (nivolumab) user spending time outdoors with his grandchildren.

Clinical trial results for
early-stage non-small cell lung cancer (NSCLC) before and after surgery

Given before and after surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery

Actor portrayals.
OPDIVO + chemotherapy and OPDIVO alone is not approved for people younger than 18 years of age.

An FDA-approved combination of immunotherapy and chemotherapy before surgery and immunotherapy alone after surgery that helped reduce the risk of cancer spreading or returning compared to chemotherapy alone before surgery.

This pre-surgery and post-surgery immunotherapy treatment may offer you an additional way to treat your condition. Before surgery, these treatments help shrink tumors. After surgery, they attack cancer cells that may remain “hidden” or hard to see and aim to keep them from coming back.

image treatment plan

About the clinical trial

In a clinical trial of 461 people with early-stage NSCLC who were able to have surgery, 229 people were given OPDIVO + chemotherapy before surgery followed by OPDIVO alone after surgery, and 232 people were given platinum-based chemotherapy before surgery followed by placebo after surgery.

More people given the OPDIVO-based treatment did not have their cancer return or spread compared to chemotherapy alone at a minimum follow-up of 16 months

76%  given OPDIVO® + chemo, then OPDIVO® alone didn't have their cancer spread or return, compared to 61% given placebo + chemo then placebo alone.

Ask your doctor if this OPDIVO-based treatment is right for you.

OPDIVO + chemotherapy and OPDIVO alone will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For adults with early-stage non-small cell lung cancer (NSCLC) before and after surgery

OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC that does not have an abnormal EGFR or ALK gene, and then may be continued alone after surgery to help prevent your lung cancer from coming back.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.



1506-US-2400468 09/24